How Does It Work?
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
Diane R. Mould, PhD
Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.
Latest Blog Post
At Baysient, it is our mission to help patients achieve remission from their inflammatory diseases. The traditional dosing process for such conditions leads to expensive medical costs overall and makes long-term remission challenging to achieve and maintain. Through precision and customized dosing, Baysient’s iDose software…